TORONTO (BUSINESS WIRE) Apr 27, 2021
Li-Cycle Corp. (âLi-Cycleâ or âthe Companyâ), an industry leader in lithium-ion battery resource recovery and the largest lithium-ion battery recycler in North America, today announced that it has launched The Green-Cycle Podcast, featuring the latest news, trends, and innovations in clean technology.
The Green-Cycle Podcast hosted by Lee Constable, a notable TV personality and professional science communicator, made its official debut today with its first episode discussing the importance of lithium-ion battery recycling and resource recovery with Li-Cycleâs Co-founders Ajay Kochhar and Tim Johnston. The Green-Cycle Podcast is easily accessible and listeners can find episodes on The Green-Cycle Podcast webpage, in the Podcasts section on Li-Cycleâs website and on platforms such as Apple Podcasts and Spotify.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the .
CRISPR Therapeutics AGApril 26, 2021 GMT
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous,
ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 was previously granted PRIME designation for the treatment of sickle cell disease (SCD) in 2020.
Bookmark of this page has been deleted.
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma
REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. ( CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC), has achieved the pre-specified primary endpoints of progression free survival (PFS) and overall survival (OS) at the interim analysis. JUPITER-06 is a randomized, double-blind, placebo-controlled, multi-center, phase 3 clinical trial initiated in 2019 with 514 patients enrolled.
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Atlantic Power Obtains Final Court Order Approving Arrangement
News provided by
Share this article
Share this article
DEDHAM, Mass., April 19, 2021 /PRNewswire/ Atlantic Power Corporation (NYSE: AT) (TSX: ATP) ( Atlantic Power or the Company ) announced today that it has obtained a final court order from the Supreme Court of British Columbia approving its previously announced arrangement with certain affiliates (collectively the Purchasers ) of infrastructure funds managed by I Squared Capital Advisors (US) LLC.
The previously announced transaction with the Purchasers (the Transaction ) remains subject to the satisfaction or waiver of certain conditions, including approval of the holders of the Company s convertible debentures ( Convertible Debentures ), certain remaining regulatory approvals and third-party consents, and other customary closing conditions. As previously disclosed, the parties intend to close the Transaction without the approval of the holders of the Conve